A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Trial ID or NCT#

NCT06679946

Status

recruiting iconRECRUITING

Purpose

The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.

Official Title

An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Eligibility Criteria

Ages Eligible for Study: Older than 18
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Patients who are participating in the patisiran parent studies ALN-TTR02-011 or ALN-TTR02-014 or who have completed the 24-month OLE Period in the vutrisiran parent study ALN-TTRSC02-003
Exclusion Criteria:
  1. * Has permanently discontinued study drug administration while participating in the parent studies, ALN-TTR02-011, ALN-TTR02-014, or ALN-TTRSC02-003* Future or current participation in another investigational device or drug study, scheduled to occur during this study* Has other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation
View All Criteria
Show Less

Investigator(s)

Ronald M Witteles
Ronald M Witteles
Cardiologist, Heart failure cardiologist
Professor of Medicine (Cardiovascular Medicine)
SEND MESSAGE

View on ClinicalTrials.gov